TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.
|Number of pages||7|
|Journal||Biochemical Society Transactions|
|Early online date||22 May 2012|
|Publication status||Published - 1 Jun 2012|
|Event||Biochemical Society Annual Symposium: Frontiers in Biological Catalysis - Robinson College, Cambridge, United Kingdom|
Duration: 10 Jan 2012 → 12 Jan 2012